Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enlivex Therapeutics Ltd
(NQ:
ENLV
)
1.230
-0.030 (-2.38%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enlivex Therapeutics Ltd
< Previous
1
2
3
4
5
Next >
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
July 23, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 19, 2024
Via
ACCESSWIRE
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV)
July 17, 2024
Via
AB Newswire
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
June 24, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
June 20, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
June 17, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
June 03, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
May 29, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
May 28, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 29, 2024
Via
Benzinga
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
April 29, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
April 22, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
April 16, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
April 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Nasdaq Jumps 250 Points; Crude Oil Down 1%
April 11, 2024
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83....
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
April 11, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Via
Benzinga
Dow Dips 100 Points; CarMax Earnings Miss Views
April 11, 2024
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday.
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
April 11, 2024
U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
April 11, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023
April 05, 2024
ENLV stock results show that Enlivex Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
March 22, 2024
Via
ACCESSWIRE
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
February 26, 2024
Via
ACCESSWIRE
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
February 21, 2024
Via
ACCESSWIRE
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
February 07, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
January 17, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) Leading the Way in Tuesday Trading Based on Percentage Gain
January 02, 2024
Via
Investor Brand Network
Exposures
COVID-19
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
December 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 26, 2023
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth...
Via
Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.